Source: International Business Times
James Tissot Slack Capital Many biotech investments come down to a concentrated bet that Wall Street has become all too familiar with: the reliance on a single lead asset within a narrow development pipeline. Investors often accept long stretches between catalysts for a make-or-break outcome. While this investment approach can lead to substantial shareholder gains, it also exposes investors to repeated equity dilution from capital-intensive development programs, long periods before meaningful value is realised, and continued exposure to binary risk.
Go to Source
Related News
